LAS VEGAS, Nevada — Risankizumab (Skyrizi, AbbVie) provides early and lasting benefits for patients with Crohn’s disease, phase 3 trials
Risankizumab Has Early and Lasting Benefits in Crohn’s Disease
Home »
SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion
A recent study by researchers in Switzerland found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding
Neurologic Drug Prices Jump 50% in Five Years
Medicare payments for branded neurologic drugs jumped 50% over a 5-year period, while claims for these medications increased by just